Table 3.

Disease-specific variables associated with FMD and biomarkers levels.

Parameter	Univariate Analysis	Multivariate Analysis
FMD	Ro/SS-A antibodies (r = 0.34, p = 0.03) pulmonary involvement (r = 0.52, p = 0.001) ESSPRI (r = −0.40, p = 0.01) ADMA (r = −0.35, p = 0.05) VEGF (r = −0.44, p = 0.006) L-arginine (r = 0.35, p = 0.03)	Ro/SS-A antibodies (β = 0.3, p = 0.04) pulmonary involvement (β = 0.45, p = 0.003)
ADMA	ESSDAI (r = 0.33, p = 0.02) SCORE (r = 0.57, p = 0.00003) focus score (r = 0.38, p = 0.04)	ESSDAI (β = 0.24, p = 0.04)
cGMP	disease duration (r = −0.31, p = 0.03)
VEGF	hypocomplementaemia (r = 0.40, p = 0.005)
angiostatin	RF (r = 0.53, p = 0.0001) ESR (r = 0.64, p = 0.000001) Ro/SS-A antibodies (r = −0.31, p = 0.03) hypergammaglobulinemia (r = −0.51, p = 0.0002)

Abbreviations: ADMA—asymmetric dimethylarginine, cGMP—cyclic guanosine monophosphate, ESR—erythrocyte sedimentation rate, ESSDAI—EULAR Sjogren’s Syndrome Disease Activity Index, ESSPRI—EULAR Sjogren’s Syndrome Patient Reported Index, FMD—flow mediated dilation, RF—rheumatoid factor, SCORE—Systematic Coronary Risk Evaluation, VEGF—vascular endothelial growth factor.